Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

By A. Palumbo, R. Hájek, M. Delforge, M. Kropff, M. Petrucci, J. Catalano, H. Gisslinger, W. Wiktor-Jedrzejczak, M. Zodelava, K. Weisel and 17 more. New England Journal of Medicine, 2012

748 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/801851c05083f67a240a5318cdba2f29b24004ed

Citations in the corpus

• Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016, neutral): “Acute renal failure‡ 31 (9) 7 (2) 2 (<1) 41 (11) 12 (3) 4 (1)”
• Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma (2012, neutral): “Complete response 67 (29) 79 (34) 146 (32)”